BeyondSpring, Inc. (NASDAQ:BYSI) headquartered in New York, will host a conference call for the investment community to discuss the 2Q20 financial results on 3rd September 2020 at 8:00 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.beyondspringpharma.com
Earnings Expectation
BeyondSpring, Inc. a clinical stage biopharmaceutical company, is expected to report second quarter earnings results, before market open, on Thursday 3rd September 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.57 per share. Looking ahead, the full year loss are expected at $ 2.39 per share.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The companys lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer.
